Randomized Phase II Trial of Bevacizumab plus Everolimus versus Bevacizumab Alone for Recurrent or Persistent Ovarian, Fallopian Tube or Peritoneal Carcinoma: an NRG Oncology/Gynecologic Oncology Group Study

PURPOSE: Bevacizumab (BV) monotherapy leads to compensatory upregulation of multiple signaling pathways, resulting in mTOR activation. We evaluated combining BV and everolimus (EV), an mTOR kinase inhibitor, to circumvent BV-resistance in women with recurrent or persistent ovarian, fallopian tube or...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gynecol Oncol
Hlavní autoři: Tew, William P., Sill, Michael W., Walker, Joan L., Secord, Angeles Alvarez, Bonebrake, Albert J., Schilder, Jeanne M., Stuckey, Ashley, Rice, Laurel, Tewari, Krishnansu S., Aghajanian, Carol A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6350932/
https://ncbi.nlm.nih.gov/pubmed/30177462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.08.027
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky